Entity

Time filter

Source Type

Montreal, Canada

Patent
Micropharma | Date: 2014-08-15

Various embodiments are described herein for a device and method for an ingestible medical device with a rotatable element. In some described embodiments, the ingestible medical device includes a storage sub-unit with multiple chambers each having an opening for collecting or dispensing substances from the GI tract. The device further comprises a chamber enclosure with an access port. One of the chamber enclosure and the storage sub-unit are rotatable to allow for aligning the access port with a chamber opening. The ingestible medical device includes a sensor for positioning the access port of the chamber enclosure or the storage sub-unit as one of these elements rotates.


Jones M.L.,Micropharma | Ganopolsky J.G.,Micropharma | Martoni C.J.,Micropharma | Labbe A.,Micropharma | And 2 more authors.
Gut Microbes | Year: 2014

The human gastrointestinal tract hosts a large number of microbial cells which exceed their mammalian counterparts by approximately 3-fold. The genes expressed by these microorganisms constitute the gut microbiome and may participate in diverse functions that are essential to the host, including digestion, regulation of energy metabolism, and modulation of inflammation and immunity. The gut microbiome can be modulated by dietary changes, antibiotic use, or disease. Different ailments have distinct associated microbiomes in which certain species or genes are present in different relative quantities. Thus, identifying specific disease-associated signatures in the microbiome as well as the factors that alter microbial populations and gene expression will lead to the development of new products such as prebiotics, probiotics, antimicrobials, live biotherapeutic products, or more traditional drugs to treat these disorders. Gained knowledge on the microbiome may result in molecular lab tests that may serve as personalized tools to guide the use of the aforementioned products and monitor interventional progress. © 2014 Landes Bioscience. Source


Omar J.M.,University of Manitoba | Chan Y.-M.,University of Manitoba | Jones M.L.,McGill University | Jones M.L.,Micropharma | And 3 more authors.
Journal of Functional Foods | Year: 2013

Modification of gut microflora has been reported as altering energy and lipid homeostasis, leading to changes in body composition. We evaluated whether consumption of Lactobacillus amylovorus (LA) and Lactobacillus fermentum (LF) as novel probiotics alters body adiposity through modification of gut microflora. Healthy, but overweight participants (n=28) consumed yogurt containing 1.39×109 colony-forming unit (CFU) microencapsulated LA, 1.08×109CFU microencapsulated LF, or a control yogurt using a randomized, double-blind crossover design. Body composition measurements showed that body fat mass was reduced in all treatments, with the greatest reduction from LA consumption. Bacterial distribution of gut microflora determined a significant reduction in the abundance of Clostridial cluster IV from LA consumption and significant increases in the abundance of Lactobacillus in both LF and LA treatments. The results suggest that modulation of gut microbial composition from probiotic consumption may contribute to altered energy metabolism and body composition. © 2012 Elsevier Ltd. Source


Jones M.L.,McGill University | Ganopolsky J.G.,McGill University | Ganopolsky J.G.,Micropharma | Labbe A.,McGill University | And 2 more authors.
Applied Microbiology and Biotechnology | Year: 2010

Microbial and fungal infections are a significant consideration in the etiology of all wounds. Numerous antimicrobial and antifungal formulations have been developed with varying degrees of efficacy and stability. Here, we report a nitric oxide producing probiotic adhesive patch device and investigate its antimicrobial and antifungal efficacy in vitro. This probiotic patch utilizes the metabolic activity of immobilized lactic acid bacteria, glucose, and nitrite salts for the production of gaseous nitric oxide (gNO), which is used as an antimicrobial agent against bacterial and fungal pathogens. Results show that application of gNO-producing probiotic patches to cultures of E. coli, S. aureus, P. aeruginosa, MRSA, T. mentagrophytes, and T. rubrum resulted in complete cell death at between 4 and 8 h, and application to cultures of A. baumannii, resulted in fewer than ten colonies detected per milliliter at 6 h. These results demonstrate that a gNO-producing probiotic patch device containing bacteria, glucose, and nitrite salts can produce sufficient levels of gNO over a therapeutically relevant duration to kill common bacterial and fungal wound pathogens in humans. © Springer-Verlag 2010. Source


Jones M.L.,McGill University | Jones M.L.,Micropharma | Martoni C.J.,Micropharma | Prakash S.,McGill University | Prakash S.,Micropharma
European Journal of Clinical Nutrition | Year: 2012

Background/Objectives:The percentage of hypercholesterolemic individuals not reaching their LDL-cholesterol (LDL-C) goal remains high and additional therapeutic strategies should be evaluated. The objective of this study was to evaluate the cholesterol-lowering efficacy and mechanism of action of bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 capsules in hypercholesterolemic adults.Subjects/Methods:A total of 127 subjects completed a randomized, double-blind, placebo-controlled, parallel-arm, multicenter study. Subjects were randomized to consume L. reuteri NCIMB 30242 capsules or placebo capsules over a 9-week intervention period. The primary outcome was LDL-C relative to placebo at the study end point.Results:L. reuteri NCIMB 30242 capsules reduced LDL-C by 11.64% (P0.001), total cholesterol by 9.14%, (P0.001), non-HDL-cholesterol (non-HDL-C) by 11.30% (P0.001) and apoB-100 by 8.41% (P0.002) relative to placebo. The ratios of LDL-C/HDL-cholesterol (HDL-C) and apoB-100/apoA-1 were reduced by 13.39% (P0.006) and 9.00% (P0.026), respectively, relative to placebo. Triglycerides and HDL-C were unchanged. High-sensitivity C-reactive protein and fibrinogen were reduced by 1.05 mg/l (P0.005) and 14.25% (P0.004) relative to placebo, respectively. Mean plasma deconjugated bile acids were increased by 1.00 nmol/l (P0.025) relative to placebo, whereas plasma campesterol, sitosterol and stigmasterol were decreased by 41.5%, 34.2% and 40.7%, respectively.Conclusions:The present results suggest that the deconjugation of intraluminal bile acids results in reduced absorption of non-cholesterol sterols and indicate that L. reuteri NCIMB 30242 capsules may be useful as an adjunctive therapy for treating hypercholesterolemia. © 2012 Macmillan Publishers Limited. Source

Discover hidden collaborations